Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors()

PURPOSE: Advanced NSCLC harboring epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors (TKIs) typically progresses after initial response due to acquired resistance. TKIs are often continued beyond progressive disease by RECIST. We investigated the practice...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Nishino, Mizuki, Cardarella, Stephanie, Dahlberg, Suzanne E., Jackman, David M., Ramaiya, Nikhil H., Hatabu, Hiroto, Rabin, Michael S., Jänne, Pasi A., Johnson, Bruce E.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2012
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3580850/
https://ncbi.nlm.nih.gov/pubmed/23254265
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2012.11.007
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia